Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability

International Journal of Immunopathology and Pharmacology

Volumn 29, Issue 4, 2016, Pages 769-774

  Cortese, Sara ^a   Gatta, Alessia ^a   Della Valle, Loredana ^a   Mangifesta, Rocco ^a   Di Giampaolo, Luca ^a   Cavallucci, Enrico ^a   Petrarca, Claudia ^b   Paganelli, Roberto ^a   Di Gioacchino, Mario ^a,b  

^a G d Annunzio University   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bronchial hyperreactivity; Fluticasone formoterol association; Methacholine; Peak expiratory flow (PEF) variability

Indexed keywords

FLUTICASONE; FORMOTEROL; METHACHOLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHOCONSTRICTING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL FUMARATE; METHACHOLINE CHLORIDE;

ADULT; BRONCHUS HYPERREACTIVITY; BRONCHUS REACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; MALE; MILD PERSISTENT ASTHMA; MORBIDITY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ASTHMA; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; FEMALE; FLUTICASONE; FORMOTEROL FUMARATE; HUMANS; MALE; METHACHOLINE CHLORIDE; PEAK EXPIRATORY FLOW RATE;

EID: 85016924738     PISSN: 03946320     EISSN: 20587384     Source Type: Journal    
DOI: 10.1177/0394632016650896     Document Type: Letter

References (20)

1. Dissanayake S, Jain M, Grothe B, et al. (2015) An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulmonary Pharmacology & Therapeutics 35: 19–27.
2. Foresi A, Morelli MC and Catena E (2000) Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 117: 440–446.
3. Szefler SJ, Martin RJ, King TS, et al. (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. Journal of Allergy and Clinical Immunology 109: 410–418.
4. Ram FSF, Cates CJ and Ducharme FM (2006) Long-acting beta-2agonist versus antileukotrienes as addontherapy to inhaled corticosteroids for chronic asthma. Cochrane Database of Systemic Reviews 25: CD003137.
5. Aalbers R, Vogelmeier C and Kuna P (2016) Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respiratory Medicine 111: 1–7.
6. Sin DD and Man SF (2006) Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseases. European Journal of Pharmacology 533: 28–35.
7. Chetta A, Foresi A, Del Donno M, et al. (1996) Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. American Journal of Respiratory and Critical Care Medicine 153: 910–917.
8. Riccioni G, Castronuovo M, De Benedictis M, et al. (2001) Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma. International Journal of Immunopathology and Pharmacology 14: 87–92.
9. Koenig SM1, Murray JJ, Wolfe J, et al. (2008) Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respiratory Medicine 102: 665–73.
10. Riccioni G, Di Stefano F, De Benedictis M, et al. (2001) Seasonal variability of non-specific bronchial responsiveness in asthmatic patients with allergy to house dust mites. Allergy and Asthma Proceedings 22: 5–9.
11. Thamrin C, Taylor DR, Jones SL, et al. (2010) Variability of lung function predicts loss of asthma control following withdrawal of inhaled corticosteroid treatment. Thorax 65: 403–408.
12. Koenig SM, Murray JJ, Wolfe J, et al. (2008) Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respiratory Medicine 102: 665–673.
13. Crapo RO, Casaburi R, Coates AL, et al. (2000) Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. American Journal of Respiratory and Critical Care Medicine 161: 309–329.
14. Thamrin C, Zindel J, Nydegger R, et al. (2011) Predicting future risk of asthma exacerbations by using individual conditional probabilities. Journal of Allergy and Clinical Immunology 127: 1494–1502.
15. Ducharme FM, Ni Chroinin M, Greenstone I, et al. (2010) Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 5: CD005535.
16. Cates CJ and Karner C (2013) Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 4: CD007313.
17. Barnes PJ (2002) Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. European Respiratory Journal 19: 182–191.
18. Usmani OS, Ito K, Maneechotesuwan K, et al. (2005) Glucocorticoid receptor nuclear translocation in airway cells following inhaled combination therapy. American Journal of Respiratory and Critical Care Medicine 172: 704–712.
19. Cockcroft DW and Davis BE (2006) Mechanisms of airway hyperresponsiveness. Journal of Allergy and Clinical Immunology 118: 551–559.
20. Brannan JD (2010) Bronchial hyperresponsiveness in the assessment of asthma control: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 138(2 Suppl): 11–17.